Clinical Trial Update: SB-659032 Platelet Aggregation Study [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing SB-659032 for platelet aggregation in individuals with atherosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• SB 659032

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 1 | Status: COMPLETED